1. Scrip
  2. >>Business
  3. >>Financing

NASH Contender Inventiva Backed By Euronext IPO

 
• By John Davis

The five-year-old French biotech Inventiva Pharma has raised financing on the public markets to propel its lead fibrosis/NASH product through the development pipeline.

Liver anatomy

The race to market for companies developing non-alcoholic steatohepatitis (NASH) therapies has become tighter with one competitor, the Paris-based biotech, Inventiva Pharma, raising €48m ($50.8m) in an initial public offering on Euronext, the European stock exchange, to back its R&D. The funds raised could increase to €50.4m if an over-allotment option is exercised.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

 
• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.